HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas.

AbstractBACKGROUND:
Hematopoietic progenitor cells (HPCs) are able to prepare the site for incoming neoplastic cells. Among different markers of HPCs, which one should be considered the most efficient was investigated.
PATIENTS AND METHODS:
Five hundred and seventy-nine non-metastatic lymph nodes from 49 patients affected by invasive breast cancer were submitted to an immunohistochemical comparative analysis of hematopoietic (CD34), endothelial (CD133), mesenchymal (CD117) progenitors and vascular endothelial growth factor receptor 1 (VEGFR1, also known as Flt1). The cases with an intensity-distribution score >3 were considered as high HPC expressors. Survival univariate and multivariate analyses were performed.
RESULTS:
Fifteen out of the 49 patients were recorded as HPC high expressors based on the immunohistochemical VEGFR1 staining. A highly significant relationship was found between high HPC immunoexpression and the development of distant metastasis as well as the occurrence of bone localization (p<0.001). By univariate analysis, CD133 showed a highly significant value regarding metastatic localizations in the bone; by multivariate analysis, CD133 emerged as the only independent prognostic variable.
CONCLUSION:
CD133 expression shows a potential predictive role, thus representing a helpful tool for the management of breast cancer.
AuthorsA Ieni, G Giuffrè, V Adamo, G Tuccari
JournalAnticancer research (Anticancer Res) Vol. 31 Issue 4 Pg. 1315-20 (Apr 2011) ISSN: 1791-7530 [Electronic] Greece
PMID21508381 (Publication Type: Journal Article)
Chemical References
  • AC133 Antigen
  • Antigens, CD
  • Glycoproteins
  • PROM1 protein, human
  • Peptides
  • Vascular Endothelial Growth Factor Receptor-1
Topics
  • AC133 Antigen
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD (metabolism)
  • Bone Neoplasms (metabolism, secondary)
  • Breast Neoplasms (metabolism, pathology)
  • Carcinoma, Ductal, Breast (metabolism, secondary)
  • Carcinoma, Lobular (metabolism, secondary)
  • Carcinoma, Medullary (metabolism, secondary)
  • Endothelium, Vascular (metabolism)
  • Female
  • Follow-Up Studies
  • Glycoproteins (metabolism)
  • Hematopoietic Stem Cells (metabolism)
  • Humans
  • Immunoenzyme Techniques
  • Lymph Nodes (metabolism, pathology)
  • Lymphatic Metastasis
  • Mesoderm (metabolism, pathology)
  • Peptides (metabolism)
  • Prognosis
  • Sensitivity and Specificity
  • Survival Rate
  • Vascular Endothelial Growth Factor Receptor-1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: